Recruiting PHASE2 INTERVENTIONAL 1-arm
NCT07021677
Use of a New Medicine Daratumumab to Treat Left-over Cancer in a Blood Cancer Called T Acute Lymphoblastic Leukemia (DARA_T_ALL)
Daratumumab for Minimal Residual Disease Eradication in T-Acute Lymphoblastic Leukemia - A Phase 2 Study
Sponsor: Tata Memorial Centre
Conditions
T Acute Lymphoblastic Leukemia
Interventions
Daratumumab Injection
Updated 1 time since 2025 Last updated: Jun 13, 2025 Started: Aug 28, 2023 Primary completion: Aug 28, 2026 Completion: Aug 28, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE2 trial investigates T Acute Lymphoblastic Leukemia and is currently actively recruiting participants. Tata Memorial Centre leads this study, which shows 1 recorded version since 2023 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
1 version recorded Recruiting — PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Tata Memorial Centre
Data source: Tata Memorial Centre
For direct contact, visit the study record on ClinicalTrials.gov .